Zur Rose Group, a retailer of pharmaceutical products, agreed to acquire the mail-order and diabetes activities of Apotal, a mail-order pharmacy. Financial terms were not disclosed. "Apotal has built a strongly performing OTC online business which we will develop further, capitalizing on our leading position in electronic prescription and ehealth services. Our market and innovation leadership as pre-eminent digital health services provider focusing on the future requirements of the customer health journey is thus strengthened . We are looking forward to working with the management and the entire team of Apotal as part of a stronger Zur Rose Group," Walter Oberhänsli, Zur Rose Group CEO.